Litcius/Paper detail

Flare-up of adult-onset Still's disease after receiving a second dose of BNT162b2 COVID-19 mRNA vaccine

Shintaro Yamamoto, Keisuke Nishimura, Kohei Yo, Daisuke Waki, Hiroyuki Murabe, Toshihiko Yokota

2021Clinical and Experimental Rheumatology19 citationsDOIOpen Access PDF

Abstract

Letters to the EditorsFlare-up of adult-onset Still's disease after receiving a second dose of BNT162b2 COVID-19 mRNA vaccine Sirs, Vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are essential for controlling the ongoing coronavirus disease 2019 (COVID-19) pandemic.At present, vaccination is continuing rapidly worldwide, and many individuals with rheumatic diseases have received vaccines to prevent SARS-CoV-2 infection.However, data on the safety of SARS-CoV-2 vaccines in patients with rheumatic diseases are insufficient (1).Herein, we report a case of adult-onset Still's disease (AOSD) that relapsed after SARS-CoV-2

Topics & Concepts

MedicineCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakBetacoronavirusMEDLINEVirologyPandemicInternal medicineDiseaseInfectious disease (medical specialty)OutbreakLawPolitical scienceAutoimmune and Inflammatory Disorders ResearchT-cell and Retrovirus Studies
Flare-up of adult-onset Still's disease after receiving a second dose of BNT162b2 COVID-19 mRNA vaccine | Litcius